DDInter1961 DDInter1628
A dideoxynucleoside compound in which the 3&#39;-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Zidovudine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Zidovudine {u} (Compound) downregulates {v} (Gene) OSBPL10
OSBPL10 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Zidovudine {u} (Compound) causes {v} (Side Effect) Anaemia
Anaemia {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Zidovudine {u} (Compound) downregulates {v} (Gene) OSBPL10
OSBPL10 {u} (Gene) is regulated by {v} (Gene) PLK4
PLK4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Zidovudine {u} (Compound) downregulates {v} (Gene) TUBA1A
TUBA1A {u} (Gene) is downregulated by {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Zidovudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Zidovudine {u} (Compound) downregulates {v} (Gene) OSBPL10
OSBPL10 {u} (Gene) is regulated by {v} (Gene) RPS6KA1
RPS6KA1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Zidovudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Bortezomib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Ruxolitinib
Zidovudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nilotinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Zidovudine {u} (Compound) downregulates {v} (Gene) TUBA1A
TUBA1A {u} (Gene) interacts with {v} (Gene) LRRK2
LRRK2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Zidovudine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Zidovudine (Compound) downregulates OSBPL10 (Gene) and OSBPL10 (Gene) is downregulated by Ruxolitinib (Compound)
Zidovudine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Ruxolitinib (Compound)
Zidovudine (Compound) downregulates OSBPL10 (Gene) and OSBPL10 (Gene) is regulated by PLK4 (Gene) and PLK4 (Gene) is bound by Ruxolitinib (Compound)
Zidovudine (Compound) downregulates TUBA1A (Gene) and TUBA1A (Gene) is downregulated by hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Zidovudine (Compound) downregulates OSBPL10 (Gene) and OSBPL10 (Gene) is regulated by RPS6KA1 (Gene) and RPS6KA1 (Gene) is downregulated by Ruxolitinib (Compound)
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Ruxolitinib (Compound)
Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Zidovudine (Compound) downregulates TUBA1A (Gene) and TUBA1A (Gene) interacts with LRRK2 (Gene) and LRRK2 (Gene) is bound by Ruxolitinib (Compound)